EGFR and non-small cell lung carcinoma: In advanced NSCLC harboring EGFR-sensitive mutations, it has become a consensus that TKIs should be preferred for first-line treatment, but the effective response rates to first-generation TKIs such as gefitinib and erlotinib and the next-generation drugs such as afatinib and oxetinib are less than 80% [7, 8].